# Southeast Asia’s RNAi Technology Market Poised for Rapid Expansion, Projected to Soar by 2033

- Link: https://www.thailand-business-news.com/health/303532-southeast-asias-rnai-technology-market-poised-for-rapid-expansion-projected-to-soar-by-2033
- Published: 2026-04-27T11:37:46+07:00
- Author: J. Allan

Southeast Asia is quietly emerging as one of the most dynamic frontiers in RNA interference(
RNAi) biotechnology, as governments, academic institutions, and pharmaceutical companies
converge on a technology once confined to Western research labs

## Key takeaways

 * Southeast Asia’s RNAi technology market, valued at USD 80.20 million in 2024,
   is set to grow at a striking 16.25% CAGR through 2033, driven by rising government
   support and expanding pharmaceutical R&D investment across the region.
 * Singapore dominates the regional landscape, cementing its position as Asia’s 
   premier precision medicine hub through landmark collaborations with global pharma
   giants including Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk.
 * siRNA leads all RNAi modalities as the most commercially mature technology, with
   breakthrough research, such as NUS Medicine’s lipid nanoparticle therapy for 
   liver disease, underscoring its growing clinical and commercial relevance across
   Southeast Asia.

 A new [industry analysis](https://univdatos.com/reports/southeast-asia-rnai-technology-market)
covering the period through 2033 paints a striking picture of accelerating momentum,
and the numbers are hard to ignore.

ADVERTISEMENT

According to a comprehensive market report published by UnivDatos Market Insights,
the Southeast Asia RNAi Technology Market was valued at approximately USD 80.20 
million in 2024 and is projected to expand at a compound annual growth rate (CAGR)
of roughly 16.25% through 2033. That trajectory, driven by a confluence of government
policy, academic-industry collaboration, and surging demand for precision medicine,
would place the region firmly on the global map for RNA-based therapeutics and research
services.

## What Is RNAi, and Why Does It Matter?

RNA interference is a gene-silencing mechanism that enables scientists to selectively
suppress the activity of specific genes using short interfering molecules. In practical
terms, it offers researchers a molecular scalpel: the ability to turn off disease-
causing genes with extraordinary precision. Since its discovery earned a Nobel Prize
in 2006, RNAi has moved steadily from the laboratory bench toward clinical application,
finding use in drug discovery, rare disease treatment, oncology, and metabolic disorder
research.

In Southeast Asia, the technology is gaining traction precisely because it shortens
drug development timelines, reduces the cost of target validation, and integrates
well with the outsourcing models increasingly favored by pharmaceutical companies
seeking efficiency in a competitive global market.

### Related**Posts**

###  󠀁[ASEAN’s Digital Economy Framework Agreement (DEFA): Key Insights for Foreign Businesses](https://www.thailand-business-news.com/asean/335623-aseans-digital-economy-framework-agreement-defa-key-insights-for-foreign-businesses)󠁿

###  󠀁[World Bank Group Launches First Digital Strategy to Close Global Digital Divide](https://www.thailand-business-news.com/tech/335373-world-bank-group-launches-first-digital-strategy-to-close-global-digital-divide)󠁿

###  󠀁[Singapore Pillar Two Registration: Steps Multinational Groups Should Take](https://www.thailand-business-news.com/asean/329970-singapore-pillar-two-registration-what-multinational-groups-need-to-do)󠁿

###  󠀁[ASEAN’s Data Center Boom Puts Sustainability Goals to the Test](https://www.thailand-business-news.com/asean/312509-aseans-data-center-boom-puts-sustainability-goals-to-the-test)󠁿

## siRNA Dominates the Market Landscape

Among the various RNAi modalities, which include short hairpin RNA (shRNA) and microRNA(
miRNA), short interfering RNA, or siRNA, commands the largest share of the regional
market. Its dominance reflects a straightforward reality: siRNA is the most clinically
validated and commercially mature format, supported by established delivery systems
and a proven track record in rare diseases, oncology, and metabolic conditions.

A noteworthy example of siRNA’s real-world potential emerged from Singapore in late
2025, when researchers at NUS Medicine announced a novel RNA-based therapy for metabolic
dysfunction-associated steatohepatitis (MASH), a liver condition affecting approximately
25% of people globally and up to 40% of adults in Singapore. The team used lipid
nanoparticles to deliver siRNA directly into liver cells, where it silenced a gene
called SPTLC2 that drives the accumulation of ceramides, fat-like molecules linked
to liver inflammation and fibrosis. The breakthrough illustrated exactly the kind
of translational research driving long-term commercial demand for siRNA tools across
the region.

## Pharma and Biotech Companies Lead Adoption

On the end-user side, pharmaceutical and biotechnology companies represent the dominant
segment. Their strategy is clear: use RNAi technology to de-risk drug targets before
committing to expensive clinical investment, thereby improving development efficiency
and pipeline diversity. Southeast Asia’s pharma companies are increasingly outsourcing
RNAi-based discovery efforts, a trend that is catalyzing the growth of specialized
service providers and contract development and manufacturing organizations (CDMOs)
throughout the region.

A notable example of this dynamic came in April 2025, when GenScript Biotech Corporation,
a global leader in biotechnology research services, announced a strategic partnership
with NSG Bio, Singapore’s premier biotech incubator. Under the agreement, GenScript
committed to offering preferential rates and expert technical guidance across its
full range of biotech services to incubator residents, a direct investment in the
kind of early-stage ecosystem that feeds long-term RNAi adoption.

## Singapore: The Undisputed Regional Hub

If there is one country that defines Southeast Asia’s RNAi ambitions, it is Singapore.
The city-state’s combination of world-class intellectual property protections, a
proactive government, deep life-science infrastructure, and proximity to global 
pharmaceutical leaders has made it the region’s dominant commercialization hub for
RNA technologies.

The most striking signal of Singapore’s position came in December 2025, when Precision
Health Research, Singapore (PRECISE) announced a landmark collaboration with four
global pharmaceutical giants, Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk,
under Phase II of Singapore’s National Precision Medicine (NPM) programme. The initiative
marked Singapore as the first country in Asia to establish a pre-competitive collaboration
with leading pharmaceutical companies, effectively setting the blueprint for how
precision medicine ecosystems should be built in the region.

Thermo Fisher Scientific’s parallel investment reinforced the picture. In December
2025, the company announced an expansion of its bioprocessing capabilities across
Asia, including a broadening of its existing Bioprocess Design Center in Singapore,
offering bench-to-pilot scale bioprocessing, expert-led training, and technical 
collaboration to help companies scale early-stage processes toward sustainable biomanufacturing.

## Vietnam: The Fastest-Growing Market to Watch

While Singapore commands today’s market, the report identifies Vietnam as the country
expected to record the highest growth rate over the forecast period. Vietnam’s emergence
reflects a broader pattern: as the biotech ecosystems of Indonesia, Thailand, the
Philippines, and Malaysia continue to mature, RNAi adoption is spreading beyond 
the region’s established innovation hubs into markets characterized by rapidly improving
lab infrastructure, growing research talent pipelines, and expanding government 
commitment to life sciences.

## The Competitive Landscape

The Southeast Asia RNAi technology space features a mix of global giants and regional
specialists. Key players operating in the market include GenScript, Integrated DNA
Technologies (a Danaher Corporation subsidiary), Thermo Fisher Scientific, Merck
KGaA, QIAGEN, Revvity, ABT Biomedical Solutions, and Bio Basic Asia Pacific. Their
growth strategies span partnerships, new product launches, geographic expansions,
and licensing agreements.

One example: in August 2025, Hongene Biotech Corporation, a CDMO focused on nucleic
acid therapeutics, secured a non-exclusive licensing agreement with UMass Chan Medical
School to produce and supply extended nucleic acid (exNA) monomers and modified 
oligonucleotides for research use. The deal expanded access to innovative oligonucleotide
technologies for both academic and biopharmaceutical researchers working on RNAi,
antisense oligonucleotides, CRISPR guides, and related modalities.

## Challenges Ahead

The road to full regional maturity is not without obstacles. The report identifies
limited local RNAi manufacturing capacity, the high cost of advanced tools, a shortage
of specialists trained in RNA technologies, and uneven regulatory frameworks across
countries as the principal headwinds. Regulatory complexity for RNA-based therapeutics
remains particularly challenging: each Southeast Asian market brings its own approval
pathways, complicating the commercialization strategies of companies seeking regional
scale.

Uneven adoption is perhaps the most structural challenge. While Singapore and, increasingly,
Malaysia and Vietnam are building the institutional and industrial scaffolding for
serious RNAi development, other markets in the region are earlier in that journey.
Bridging that gap will require sustained policy commitment, cross-border talent 
development, and deeper integration between academic research and commercial application.

## The Bigger Picture

What the Southeast Asia RNAi market ultimately represents is a test of whether the
region can convert scientific ambition into durable biotechnology competitiveness.
The ingredients are increasingly in place: government support is growing, global
companies are expanding their regional footprint, and breakthrough research, from
Singapore’s liver disease therapy to the continent-wide precision medicine collaborations,
is generating the kind of proof points that attract further investment.

At a 16.25% annual growth rate, the sector is expanding nearly twice as fast as 
the broader global healthcare market. For investors, researchers, and policymakers
with a view toward the next decade of biomedical innovation, Southeast Asia’s RNAi
story has only just begun